Copyright
©The Author(s) 2017.
World J Gastroenterol. Oct 28, 2017; 23(40): 7321-7331
Published online Oct 28, 2017. doi: 10.3748/wjg.v23.i40.7321
Published online Oct 28, 2017. doi: 10.3748/wjg.v23.i40.7321
Demographic and clinical variables | All patients | Medication adherence ranking | P value | |||
High | Medium | Low | ||||
(n = 42) | (n = 37) | (n = 21) | ||||
Age | 58.4 ± 10.2 | 57.9 ± 10.9 | 58.2 ± 9.0 | 57.8 ± 10.8 | 0.787 | |
Male gender | 65 (65.0) | 21 (50.0) | 30 (81.1) | 14 (66.7) | 0.015 | |
Primary aetiology | ALD | 49 (48.0) | 19 (45.2) | 19 (51.4) | 11 (52.4) | 0.842 |
HCV | 35 (33.0) | 14 (33.3) | 13 (35.1) | 8 (38.1) | 0.963 | |
Other | 16 (16.0) | 9 (21.5) | 5 (13.5) | 2 (9.5) | 0.383 | |
1Child-Turcotte Pugh class | A | 24 (24.0) | 6 (14.3) | 12 (32.4) | 6 (28.6) | 0.684 |
B | 59 (59.0) | 29 (69.0) | 21 (56.8) | 9 (42.8) | ||
C | 17 (17.0) | 7 (16.7) | 4 (10.8) | 6 (28.6) | ||
MELD score | 14.4 ± 5.2 | 14.6 ± 4.6 | 14.2 ± 5.1 | 14.2 ± 6.7 | 0.936 | |
Ascites at review (incl. suppressed by medication) | 80 (80.0) | 37 (88.1) | 28 (75.7) | 15 (71.4) | 0.187 | |
Encephalopathy at review (incl. suppressed by medication) | 36 (36.0) | 12 (28.6) | 13 (35.1) | 11 (52.4) | 0.184 | |
Hepatocellular carcinoma | 8 (8.0) | 3 (7.1) | 3 (8.1) | 2 (9.5) | 1.00 | |
Number of self-reported medicines | 7.1 ± 3.5 | 7.2 ± 3.7 | 7.1 ± 3.6 | 6.9 ± 3.1 | 0.923 | |
Number of comorbidities | 5.5 ± 2.8 | 5.4 ± 2.8 | 5.8 ± 3.0 | 5.2 ± 2.5 | 0.703 | |
2Unable to afford medicines | 19 (20.2) | 1 (2.5) | 12 (36.4) | 6 (28.6) | < 0.001 | |
3Education | Nil, Primary, Middle school | 39 (42.4) | 14 (34.1) | 13 (43.3) | 12 (57.1) | 0.215 |
High school, Trade, University | 53 (57.6) | 27 (65.9) | 17 (56.7) | 9 (42.9) | ||
4Employment status | Employed | 18 (19.1) | 9 (22.0) | 6 (18.2) | 3 (14.3) | 0.842 |
Government welfare | 72 (76.6) | 30 (73.2) | 25 (75.8) | 18 (85.7) | 0.602 | |
ARIA | Highly accessible | 89 (89.0) | 36 (85.7) | 34 (91.9) | 19 (90.5) | 0.713 |
Accessible–remote | 11 (11.0) | 6 (14.3) | 3 (8.1) | 2 (9.5) | ||
IRSD | Most disadvantaged | 32 (32.0) | 16 (38.1) | 7 (18.9) | 9 (42.9) | 0.093 |
Low–moderate disadvantage | 68 (68.0) | 26 (68.9) | 30 (81.1) | 12 (57.1) |
- Citation: Hayward KL, Valery PC, Martin JH, Karmakar A, Patel PJ, Horsfall LU, Tallis CJ, Stuart KA, Wright PL, Smith DD, Irvine KM, Powell EE, Cottrell WN. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. World J Gastroenterol 2017; 23(40): 7321-7331
- URL: https://www.wjgnet.com/1007-9327/full/v23/i40/7321.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i40.7321